Is cD105 a marker of tumour vasculature and a potential target for the treatment of head and neck squamous cell carcinoma?
Prospective studies are mandatory to confirm that CD105 expression is a significant prognostic hallmark in HNSCC. The results of prospective studies could be relevant for the adoption of stricter follow-up protocols and/or alternative therapeutic regimens for patients with a high CD105 expression in HNSCC. Great interest is currently being focused on vascular targeting for therapeutic purposes. Preclinical studies on appropriate animal models resembling HNSCC to investigate the effects of inhibiting CD105 may show the efficacy of combined treatment strategies associating angiogenic-targeted with conventional therapies for HNSCC.
This study confirmed that TNF-α induced the proliferation of DPSCs by regulating the Akt/GSK-3β/cyclin D1 signaling pathway and then provided a suitable number for the requirements of cell differentiation.